



James G. Yarger, Ph.D.  
Chief Executive Officer  
ENDECE Neural

## Message from ENDECE Neural

*Dear Friends,*

*As we continue to advance the pre-clinical development of our lead compound, NDC-1308, I am thrilled to share the latest progress updates with you. Pre-clinical studies have shown that NDC-1308:*

- *Induces significant remyelination in both the cortical and hippocampal brain regions using a mouse model of demyelination, in which the neurotoxicant cuprizone was used to remove the myelin sheath from the axons (nerve fibers) of mice*
- *Causes a significant increase in grip strength, compared to that observed in vehicle-treated animals. Grip strength, the force applied by the hand to pull on or suspend from objects, is a test potentially applicable to patients with MS in future clinical studies*
- *Is well-tolerated in mice, who exhibited normal animal behavior and clinical chemistries*
- *May be beneficial for treating patients with MS*

We are also pleased to report that initial safety studies of NDC-1308 have been successfully completed. Additional safety studies, which are required by the FDA, must be completed before phase 1 studies can begin.

## ENDECE Neural Receives Third Grant from NMSS to Support NDC-1308

We are pleased to announce that the National Multiple Sclerosis Society's (NMSS) Fast Forward initiative has provided a grant to ENDECE Neural to continue to advance the development of NDC-1308. The grant, the third in a series of bequests from the NMSS, will fund additional studies designed to further characterize the efficacy and safety of NDC-1308 in animals as ENDECE Neural prepares for first-in-human clinical studies of the compound, which are scheduled to launch in 2015.

## Updated NDC-1308 Data to be Presented at ACTRIMS/ECTRIMS Meeting

New data on NDC-1308 will be presented during a poster session at the 2014 joint meeting of the American and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS/ECTRIMS) on September 12 in Boston, Mass. The poster, to be presented by Steven H. Nye, Ph.D., Vice President of Discovery at ENDECE Neural, demonstrates that NDC-1308 induces remyelination of MS-damaged axons in a validated animal model of demyelination.

*“Unlike other drugs in this class, NDC-1308 has gained the ability to repair the damaged myelin sheath in a validated animal model of demyelination,” said Dr. Nye. “The latest results offer further support for the potential benefits of administering NDC-1308 to patients with MS, and we look forward to testing this approach in clinical trials.”*

Our research highlights also include an upcoming data presentation at Neuroscience 2014, the annual meeting of the Society of Neuroscience (SFN). We hope to see you at the meeting, which takes place November 15-19 in Washington, DC.